Subscribe
shutterstock_1548709493_nitpicker
nitpicker / Shutterstock.com
6 September 2021AmericasMuireann Bolger

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis (apixaban).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
18 January 2022   The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Big Pharma
Pfizer accuses ex-employees of stealing trade secrets for startup
3 February 2022   Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
18 January 2022   The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Big Pharma
Pfizer accuses ex-employees of stealing trade secrets for startup
3 February 2022   Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

More on this story

Americas
Bristol Myers can’t convince circuit to overturn $1.2bn ruling
18 January 2022   The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.
Big Pharma
Pfizer accuses ex-employees of stealing trade secrets for startup
3 February 2022   Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company.
Generics
BMS sues MSN over Pomalyst generic
7 April 2022   Bristol Myers Squibb has sued MSN Laboratories over its planned generic of Pomalyst, which it claims infringes six patents owned by BMS’ subsidiary Celgene.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility